Objective. Data on the impact of @entity2289 -675 4G/5G genotype for fibrinolysis during @entity583 are inconsistent. The aim of our study was to evaluate the association of clinical and genetic ( @entity2289 -675 4G/5G polymorphism) factors with @entity1563 in @entity1 with @entity583 . Materials and Methods. @entity2289 -675 4G/5G detection was achieved by using Sanger sequencing in a sample of @entity1 hospitalized for stent implantation due to @entity583 . We categorized the @entity1 into two groups: @entity1 with @entity1563 and @entity1 without @entity1563 according to angiographic evaluation. Results. We identified n = 122 (32.4%) 4G/4G, n = 186 (49.5%) 4G/5G, and n = 68 (18.1%) 5G/5G @entity2289 genotype carriers. Univariate and multivariate analysis showed that only the 4G/5G genotype was associated with @entity1563 (OR: 1.656 and 95% CI: 1.009-2.718, p = 0.046). Conclusions. Our results showed that carriers of @entity2289 4G/5G genotype with @entity583 have increased odds of @entity1563 more than 1.6 times in comparison to the carriers of homozygous genotypes.

The Effect of @entity2289 4G/5G Polymorphism and Clinical Factors on @entity1563 in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity1563 :: ('MESH:D054059', 'Disease') :: ['coronary artery occlusion'] @entity2289 :: ('5054', 'Gene') :: ['PAI-1']
@entity583 :: (MESH:D009203,Disease) :: ['Myocardial Infarction']
